By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Microarray firm Arrayit today said that it will be seeking pre-market approval by the US Food and Drug Administration for its OvaDx ovarian cancer test.

In a statement, the Sunnyvale, Calif., firm said that though the PMA process is more stringent than the 510(k) route, it believes it can receive Class III PMA approval for the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.